GO
| HSI1 | 23,157.97 | 0.00 | -- |
| HSCEI1 | 8,359.26 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2025-05-30 15:00:40 Despite challenges in the sales of CSPC PHARMA (01093.HK)'s NBP and Duomeisu, 1Q25 results was still in line with expectations, with net profit declining by 8.4% YoY, according to CLSA's research report. CLSA believed that CSPC PHARMA's earnings have bottomed out in 1Q25. Apart from the market-focused 'SYS6010', management also revealed two other products that are expected to reach potential licensing agreements, with a scale of over US$5 billion. CLSA continued to be optimistic about CSPC PHARMA's development, and considered its early-stage R&D pipeline globally competitive, with a differentiated innovative drug platform. Therefore, the broker kept rating on CSPC PHARMA at High Conviction Outperform, with a target price of $13.8. ~ AASTOCKS Financial News Website: www.aastocks.com | |